Skip to content
value.today

ArriVent Biopharma, Inc.

Total raised
$260 M
2 rounds on record
Latest round
$110 M
Dec 2022
First round on record
Jun 2021
Today
Went public
See the company page

ArriVent Biopharma, Inc. is listed today as ArriVent BioPharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ArriVent Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$110 MNo. 2$50 to $250 million

ArriVent Biopharma, Inc.: Raise no. 2, Dec 2022

Investors in this round

17 investors had bought by the notice of Dec 29, 2022: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for ArriVent Biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$110 M of $145 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Zhengbin (Bing) Yao · Executive Officer, Director
  • Bahija Jallal · Director
  • Carl Gordon · Director
  • Cong Xu · Director
  • James Healy · Director
  • Jason Zhang · Director
  • Stuart Lutzker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhengbin (Bing) Yao, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 29, 2022. Read the notice at the SEC.

equitySEC
Jun 2021$150 MNo. 1$50 to $250 million

ArriVent Biopharma, Inc.: Raise no. 1, Jun 2021

Investors in this round

10 investors had bought by the notice of Feb 14, 2022: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for ArriVent Biopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Zhengbin (Bing) Yao · Executive Officer, Director
  • Cong Xu · Director
  • Jason Zhang · Director
  • Stuart Lutzker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zhengbin (Bing) Yao, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 14, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ArriVent Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2022

That is all the official record says: ArriVent Biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of ArriVent Biopharma, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in ArriVent Biopharma, Inc.
InvestorKindAmountRoundRoleSource
Hillhouse Capital Management, Ltd.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2024)SEC Form 3
OrbiMed Advisors IV LtdFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
OrbiMed Asia GP IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3
OrbiMed Capital GP VIII LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 17 investors.

Largest shareholders today

Institutions holding ArriVent BioPharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ArriVent Biopharma, Inc.
NameRoleNamed in
Zhengbin (Bing) YaoExecutive officerDec 2022
Bahija JallalDirectorDec 2022
Carl GordonDirectorDec 2022
Cong XuDirectorDec 2022
James HealyDirectorDec 2022
Jason ZhangDirectorDec 2022
Stuart LutzkerDirectorDec 2022
Zhengbin (Bing) YaoDirectorDec 2022

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.